Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sepracor cuts Soltara

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Sepracor discontinues development of its antihistamine Soltara (tecastemizole, formerly norastemizole) for allergic rhinitis "after taking into consideration the results from recent tecastemizole trials [and] evaluating the changing dynamics of the U.S. antihistamine market," Sepracor reports Dec. 2. Soltara was found "not approvable" March 6, 2002 due to concerns about its QT profile (1Pharmaceutical Approvals Monthly March 1, 2002, In Brief). Sepracor said it initiated "several preclinical and clinical studies" after meeting with FDA in late 2002, but "results from some of these…trials indicate that the company would need to conduct additional studies." Soltara is the active metabolite of Janssen's Hismanal (astemizole), withdrawn from the market in June 2001 because of cardiac side effects...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS002434

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel